These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19339752)

  • 21. Speech, prosody, and voice characteristics of a mother and daughter with a 7;13 translocation affecting FOXP2.
    Shriberg LD; Ballard KJ; Tomblin JB; Duffy JR; Odell KH; Williams CA
    J Speech Lang Hear Res; 2006 Jun; 49(3):500-25. PubMed ID: 16787893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor instability in parkinsonian speech intensity.
    Ho AK; Iansek R; Bradshaw JL
    Neuropsychiatry Neuropsychol Behav Neurol; 2001; 14(2):109-16. PubMed ID: 11417664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Speech production in Parkinson's disease: II. Acoustic and electropalatographic investigation of sentence, word and segment durations.
    McAuliffe MJ; Ward EC; Murdoch BE
    Clin Linguist Phon; 2006; 20(1):19-33. PubMed ID: 16393796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Speech outcome regarding overall intelligibility, articulation, resonance and voice in Flemish children a year after pharyngeal flap surgery. A pilot study.
    Van Lierde KM; Bonte K; Baudonck N; Van Cauwenberge P; De Leenheer EM
    Folia Phoniatr Logop; 2008; 60(5):223-32. PubMed ID: 18698142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of deep brain stimulation on different speech subsystems in patients with multiple sclerosis.
    Pützer M; Barry WJ; Moringlane JR
    J Voice; 2007 Nov; 21(6):741-53. PubMed ID: 16872803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
    Azevedo LL; Souza IS; Oliveira PM; Cardoso F
    Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emotional speech in Parkinson's disease.
    Möbes J; Joppich G; Stiebritz F; Dengler R; Schröder C
    Mov Disord; 2008 Apr; 23(6):824-9. PubMed ID: 18307245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breath-group intelligibility in dysarthria: characteristics and underlying correlates.
    Yunusova Y; Weismer G; Kent RD; Rusche NM
    J Speech Lang Hear Res; 2005 Dec; 48(6):1294-310. PubMed ID: 16478372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
    Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of visible speech in the perceptual rating of pathological voices.
    Martens JW; Versnel H; Dejonckere PH
    Arch Otolaryngol Head Neck Surg; 2007 Feb; 133(2):178-85. PubMed ID: 17309988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acoustic analysis of prosody in females with Parkinson's disease: effect of L-dopa].
    Azevedo LL; Cardoso F; Reis C
    Arq Neuropsiquiatr; 2003 Dec; 61(4):995-8. PubMed ID: 14762605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perceptual and acoustic analysis of speech in individuals with spinocerebellar ataxia (SCA).
    Schalling E; Hammarberg B; Hartelius L
    Logoped Phoniatr Vocol; 2007; 32(1):31-46. PubMed ID: 17454658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspects of voice irregularity measurement in connected speech.
    Fourcin A
    Folia Phoniatr Logop; 2009; 61(3):126-36. PubMed ID: 19571547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compensatory responses to loudness-shifted voice feedback during production of Mandarin speech.
    Liu H; Zhang Q; Xu Y; Larson CR
    J Acoust Soc Am; 2007 Oct; 122(4):2405-12. PubMed ID: 17902874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orofacial Strength and Voice Quality as Outcome of Levodopa Challenge Test in Parkinson Disease.
    Lechien JR; Delsaut B; Abderrakib A; Huet K; Delvaux V; Piccaluga M; Khalife M; Harmegnies B; Saussez S; Blecic S
    Laryngoscope; 2020 Dec; 130(12):E896-E903. PubMed ID: 32239775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states.
    Goberman A; Coelho C; Robb M
    J Commun Disord; 2002; 35(3):217-39. PubMed ID: 12064785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Speech and swallowing disorders in Parkinson disease.
    Sapir S; Ramig L; Fox C
    Curr Opin Otolaryngol Head Neck Surg; 2008 Jun; 16(3):205-10. PubMed ID: 18475072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis.
    Pinho P; Monteiro L; Soares MFP; Tourinho L; Melo A; Nóbrega AC
    Codas; 2018 Oct; 30(5):e20170200. PubMed ID: 30304100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.